Novo Nordisk A/S (NYSE:NVO) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Novo Nordisk A/S (NYSE:NVO) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $43.89 and traded as high as $48.04. Novo Nordisk A/S shares last traded at $47.23, with a volume of 8,845,809 shares.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy. The milestone could broaden access to the company’s obesity treatment and improve its competitive position against Eli Lilly, although acceptance is not final marketing approval. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some valuation analysis argues that NVO could be significantly undervalued after its selloff, while easing legal or regulatory risks surrounding GLP-1 drugs could provide an additional catalyst. These are potential upside scenarios rather than confirmed developments. Novo Nordisk Stock May Be Cheap As GLP 1 Legal Risks Shift
• Neutral Sentiment: NVO recently moved above its 200-day moving average, a technical signal that may attract some buyers, though it does not resolve the company’s fundamental growth concerns. Novo Nordisk Stock Price Passes Above 200 Day Moving Average
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk to Sell from Hold and reduced its price target to 265 Danish kroner from 290 kroner. The bank cited doubts about a return to growth, intensifying Eli Lilly competition, a potential 2027 revenue cliff and an impending patent cliff. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Pipeline concerns have worsened after cardiovascular drug candidate ziltivekimab failed a late-stage trial, reducing confidence in the products expected to support medium-term growth. Novo’s 2027 Growth Rebound Faces Fresh Doubts

Wall Street Analysts Forecast Growth

NVO has been the topic of several recent analyst reports. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research note on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Stock Performance

The stock has a market capitalization of $203.02 billion, a price-to-earnings ratio of 11.12, a price-to-earnings-growth ratio of 4.25 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock has a 50-day moving average of $47.98 and a 200 day moving average of $43.88.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion for the quarter. On average, analysts expect that Novo Nordisk A/S will post 3.43 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of NVO. Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after purchasing an additional 969,916 shares during the period. Franklin Resources Inc. grew its stake in shares of Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after purchasing an additional 717,719 shares during the period. Morgan Stanley increased its holdings in Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after purchasing an additional 428,660 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S in the first quarter valued at about $287,660,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.